<DOC>
<DOCNO>EP-0640596</DOCNO> 
<TEXT>
<INVENTION-TITLE>
N-pyridazinyl-benzene (naphthalene-, biphenyl-) sulfonamide derivatives, their preparation and their use as endothelin antagonists.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3150	A61K3150	A61P900	A61P900	A61P910	A61P912	A61P1300	A61P1302	A61P1500	A61P1500	A61P4300	A61P4300	C07D23700	C07D23716	C07D23720	C07D23722	C07D23724	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	C07D	C07D	C07D	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61P9	A61P9	A61P9	A61P9	A61P13	A61P13	A61P15	A61P15	A61P43	A61P43	C07D237	C07D237	C07D237	C07D237	C07D237	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Compounds of the formula 

wherein:
 

   R is phenyl, naphthyl or biphenyl, each of which may be 
substituted with R¹, R² and R³; 

R⁴,R⁵ and R¹² are each independently 

(a)
hydrogen; 
(b)
alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, 
cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or aralkoxy, any 

of which may be substituted with Z¹, Z² and Z³; 
(c)
halo; 
(d)
hydroxyl; 
(e)
cyano; 
(f)
nitro; 
(g)
-C(O)H or -C(O)R⁶; 
(h)
-CO₂H or -CO₂R⁶; 
(i)
-SH, -S(O)
n
R⁶, -S(O)
m
-OH, 
-S(O)
m
-OR⁶, -O-S(O)
m
-R⁶, -O-S(O)
m
OH 
or -O-S(O)
m
-OR⁶; 
(j)
-Z⁴-NR⁷R⁸; 
(k)
-Z⁴-N(R¹¹)-Z⁵-NR⁹R¹⁰; or 
(l)
R⁴ and R⁵ or R⁵ and R¹² together are alkylene 
or alkenylene (either of which may be substituted with Z¹, Z² and Z³), 

completing a 4- to 8-membered saturated, unsaturated or aromatic ring 
together with the carbon atoms to which they are attached; 
provided that when R is phenyl, at least two of R⁴, R⁵ and R¹² 
are other than hydrogen;

 
R¹, R², R³, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, Z¹, Z², 

Z³, Z⁴, Z⁵, n and m are as defined in the description;
 

and pharmaceutically acceptable salts thereof are endothelin receptor 
antagonists useful, 
inter alia
, as antihypertensive agents. 
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
SQUIBB BRISTOL MYERS CO
</APPLICANT-NAME>
<APPLICANT-NAME>
BRISTOL-MYERS SQUIBB COMPANY
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
HUNT JOHN T
</INVENTOR-NAME>
<INVENTOR-NAME>
HUNT, JOHN T.
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
This invention relates to endothelin antagonists useful, 
inter alia, for treatment of hypertension. Compounds of the formula 
and pharmaceutically acceptable salts thereof are endothelin 
receptor antagonists useful, inter alia, as antihypertensive agents. 
Throughout this specification, the above symbols are defined as 
follows:
 
   R is phenyl, naphthyl or biphenyl, each of which may be 
substituted with R¹, R² and R³;
 
   R¹, R² and R³ are each independently 
(a) hydrogen; (b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, 
cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, 
aryloxy, aralkyl or aralkoxy, any of which may be 
substituted with Z¹, Z² and Z³; (c) halo; (d) hydroxyl; (e) cyano;  (f) nitro; (g) -C(O)H or -C(O)R⁶; (h) -CO₂H or -CO₂R⁶; (i) -SH, -S(O)nR⁶, -S(O)m-OH, -S(O)m-OR⁶, 
-O-S(O)m-R⁶, -O-S(O)mOH or -O-S(O)m-OR⁶; (j) -Z⁴-NR⁷R⁸; or (k) -Z⁴-N(R¹¹)-Z⁵-NR⁹R¹⁰;    R⁴, R⁵ and R¹² are each independently 
(a) hydrogen; (b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, 
cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, 
aryloxy, aralkyl or aralkoxy, any of which may be 
substituted with Z¹, Z² and Z³; (c) halo; (d) hydroxyl; (e) cyano; (f) nitro; (g) -C(O)H or -C(O)R⁶; (h) -CO₂H or -CO₂R⁶; (i) -SH, -S(O)nR⁶, -S(O)m-OH, S(O)m-OR⁶, 
-O-S(O)m-R⁶, -O-S(O)mOH or -O-S(O)m-OR⁶; (j) -Z⁴-NR⁷R⁸; (k) -Z⁴-N(R¹¹)-Z⁵-NR⁹R¹⁰; or (l) R⁴ and R⁵, or R⁵ and R¹² together are alkylene or 
alkenylene (either of which may be substituted with 
Z¹, Z² and Z³), completing a 4- to 8-membered 
saturated, unsaturated or aromatic ring together 
with the carbon atoms to which they are attached;    provided that when R is phenyl, at least two of R⁴, R⁵ and 
R¹² are other than hydrogen;
 
   R⁶ is alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, 
cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl, any 
of which may be substituted with Z¹, Z² and Z³;
 
   R⁷ is  (a) hydrogen; (b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, 
cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl 
or aralkyl, any of which may be substituted with Z¹, 
Z² and Z³; (c) cyano; (d) hydroxyl; (e) -C(O)H or -C(O)R⁶; (f) -CO₂R⁶; or (g) -SH, -S(O)nR⁶, -S(O)m-OR⁶, 
-O-S(O)m-R⁶ or -O-S(O)m-OR⁶, except when Z⁴ is 
-S(O)n-;    R⁸ is 
(a) hydrogen; (b) -C(O)H or -C(O)R⁶, except when Z⁴ is -C(O)- and 
R⁷ is -C(O)H, -C(O)R⁶ or -CO₂R⁶; or (c) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, 
cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl 
or aralkyl, any of which may be substituted with Z¹, 
Z² and Z³; or    R⁷ and R⁸ together are
</DESCRIPTION>
<CLAIMS>
A compound of the formula 
 

or such a compound in pharmaceutically acceptable salt form, 
wherein: 

   R is phenyl, naphthyl or biphenyl, each of which may be 
substituted with R¹, R² and R³; 

   R¹, R² and R³ are each independently 

(a) hydrogen; 
(b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, 
cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, 

aryloxy, aralkyl or aralkoxy, any of which may be 
substituted with Z¹, Z² and Z³; 
(c) halo; 
(d) hydroxyl; 
(e) cyano; 
(f) nitro; 
(g) -C(O)H or -C(O)R⁶; 
(h) -CO₂H or -CO₂R⁶; 
(i) -SH, -S(O)nR⁶, -S(O)m-OH, -S(O)m-OR⁶, 
O-S(O)m-R⁶ -O-S(O)mOH or -O-S(O)m-OR⁶; 
(j) -Z⁴-NR⁷R⁸; or 
(k) -Z⁴-N(R¹¹)-Z⁵-NR⁹R¹⁰; 
 
   R⁴, R⁵ and R¹² are each independently 


(a) hydrogen; 
(b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, 
cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, 

aryloxy, aralkyl or aralkoxy, any of which may be 
substituted with Z¹, Z² and Z³; 
(c) halo; 
(d) hydroxyl; 
(e) cyano; 
(f) nitro; 
(g) -C(O)H or -C(O)R⁶; 
(h) -CO₂H or -CO₂R⁶; 
(i) -SH, -S(O)nR⁶, -S(O)m-OH, -S(O)m-OR⁶, 
-O-S(O)m-R⁶, -O-S(O)mOH or -O-S(O)m-OR⁶; 
(j) -Z⁴-NR⁷R⁸; 
(k) -Z⁴-N(R¹¹)-Z⁵-NR⁹R¹⁰; or 
(l) R⁴ and R⁵, or R⁵ and R¹² together are alkylene or 
alkenylene (either of which may be substituted with 

Z¹, Z² and Z³), completing a 4- to 8-membered 
saturated, unsaturated or aromatic ring together 

with the carbon atoms to which they are attached; 
 
   provided that when R is phenyl, at least two of R⁴, R⁵ and 

R¹² are other than hydrogen; 
   R⁶ is alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, 

cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl, any 
of which may be subs
tituted with Z¹, Z² and Z³; 
   R⁷ is 


(a) hydrogen; 
(b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, 
cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl 

or aralkyl, any of which may be substituted with Z¹, 
Z² and Z³; 
(c) cyano; 
(d) hydroxyl; 
(e) -C(O)H or -C(O)R⁶; 
(f) -CO₂R⁶; or 
(g) -SH, -S(O)nR⁶, -S(O)m-OR⁶, 
-O-S(O)m-R⁶ or -O-S(O)m-OR⁶, except when Z⁴ is 

-S(O)n-; 
 
   R⁸ is 
(a) hydrogen; 
(b) -C(O)H or -C(O)R⁶, except when Z⁴ is -C(O)- and 
R⁷ is -C(O)H, -C(O)R⁶ or -CO₂R⁶; or 
(c) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, 
cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl 

or aralkyl, any of which may be substituted with Z¹, 
Z² and Z³; or 
 
   R⁷ and R⁸ together are alkylene or alkenylene (either of 

which may be substituted with Z¹, Z² and Z³), completing a 3- to 8- 
membered saturated, unsaturated or aromatic ring together with 

the nitrogen atom to which they are attached; 
   R⁹ is 


(a) hydrogen; 
(b) hydroxyl; 
(c) -C(O)H or -C(O)R⁶; 
(d) -CO₂R⁶; 
(e) -SH, -S(O)nR⁶, -S(O)m-OR⁶, 
-O-S(O)m-R⁶ or -O-S(O)m-OR⁶; or 
(f) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, 
cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl 

or aralkyl, any of which may be substituted with Z¹, 
Z² and Z³; 
 
   R¹⁰ is 


(a) hydrogen; 
(b) -C(O)H or -C(O)R⁶, except when Z⁵ is -C(O)- and 
R⁹ is -C(O)H, -C(O)R⁶ or -CO₂R⁶; or 
(c) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, 
cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl 

or aralkyl, any of which may be substituted with Z¹, 
Z² and Z³; 
 
   R¹¹ is 


(a) hydrogen; 
(b) hydroxyl or -CO₂R⁶, except when one of R⁹ and 
R¹⁰ is hydroxyl or -CO₂R⁶; 
(c) -C(O)H or -C(O)R⁶; or 
(d) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, 
cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl 

or aralkyl, any of which may be substituted with Z¹, 
Z² and Z³; 
 
or any two of R⁹, R¹⁰ and R¹¹ together are alkylene or alkenylene 

(either of which may be substituted with Z¹, Z² and Z³), completing 
a 3- to 8-membered saturated, unsaturated or aromatic ring 

together with the atoms to which they are attached; 
   Z¹, Z² and Z³ are each independently 


(a) hydrogen; 
(b) halo; 
(c) hydroxy; 
(d) alkyl, alkenyl, aralkyl, alkoxy, aryloxy or aralkoxy; 
(e) -SH, -S(O)nZ⁶, -S(O)m-OH, -S(O)m-OZ⁶, 
-O-S(O)m-Z⁶, -O-S(O)mOH or -O-S(O)m-OZ⁶; 
(f) oxo; 
(g) nitro; 
(h) cyano; 
(i) -C(O)H or -C(O)Z⁶; 
(j) -CO₂H or -CO₂Z⁶; or 
(k) -Z⁴-NZ⁷Z⁸, Z⁴-N(Z¹¹)-Z⁵Z⁶ or 
-Z⁴-N(Z¹¹)-Z⁵-NZ⁷Z⁸; 
 
   Z⁴ and Z⁵ are each independently 


(a) a single bond; 
(b) -Z⁹-S(O)m-Z¹⁰; 
(c) -Z⁹-C(O)-Z¹⁰; 
(d) -Z⁹-C(S)-Z¹⁰; 
(e) -Z⁹-O-Z¹⁰; 
(f) -Z⁹-S-Z¹⁰; 
(g) -Z⁹-O-C(O)-Z¹⁰; or 
(h) alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, 
cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl, any 

of which may be substituted with Z¹, Z² and Z³; 
 
   Z⁶, Z⁷ and Z⁸ are each independently hydrogen, alkyl, 

 
alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, 

cycloalkenylalkyl, aryl, or aralkyl, or Z⁷ and Z⁸ together are 
alkylene or alkenylene, completing a 3- to 8-membered saturated, 

unsaturated or aromatic ring together with the nitrogen atom to 
which they are attached; 

   Z⁹ and Z¹⁰ are each independently a single bond, 
alkylene, alkenylene or alkynylene, 

   Z¹¹ is 

(a) hydrogen; 
(b) hydroxyl; 
(c) -C(O)H, -C(O)Z⁶ or -CO₂Z⁶, provided that when 
Z¹¹ is -CO₂Z⁶, Z⁶ is other than hydrogen; or 
(d) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, 
cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl 

or aralkyl; 
 
   or any two of Z⁷, Z⁸ and Z¹¹ together are alkylene or 

alkenylene, completing a 3- to 8- membered saturated, 
unsaturated or aromatic ring together with the atoms to which they 

are attached; 
   m is 1 or 2; and 

   n is 0, 1 or 2. 
A compound of the formula 
 

or such a compound in pharmaceutically acceptable salt form, 
wherein: 

   R is naphthyl or biphenyl, each of which may be 
substituted with R¹, R² and R³;

 
   R¹, R² and R³ are each independently 


(a) hydrogen; 
(b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, 
cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, 

aryloxy, aralkyl or aralkoxy, any of which may be 
substituted with Z¹, Z² and Z³; 
(c) halo; 
(d) hydroxyl; 
(e) cyano; 
(f) nitro; 
(g) -C(O)H or -C(O)R⁶; 
(h) -CO₂H or -CO₂R⁶; 
(i) -SH, -S(O)nR⁶, -S(O)m-OH, -S(O)m-OR⁶, 
-O-S(O)m-R⁶, -O-S(O)mOH or -O-S(O)m-OR⁶; 
(j) -Z⁴-NR⁷R⁸; or 
(k) -Z⁴-N(R¹¹)-Z⁵-NR⁹R¹⁰; 
 
   R⁴, R⁵ and R¹² are each independently 


(a) hydrogen; 
(b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, 
cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, 

aryloxy, aralkyl or aralkoxy, any of which may be 
substituted with Z¹, Z² and Z³; 
(c) halo; 
(d) hydroxyl; 
(e) cyano; 
(f) nitro; 
(g) -C(O)H or -C(O)R⁶; 
(h) -CO₂H or -CO₂R⁶; 
(i) -SH, -S(O)nR⁶, S(O)m-OH, -S(O)m-OR⁶, 
-O-S(O)m-R⁶, -O-S(O)mOH or -O-S(O)m-OR⁶; 
(j) -Z⁴-NR⁷R⁸; 
(k) -Z⁴-N(R¹¹)-Z⁵-NR⁹R¹⁰; or 
(l) R⁴ and R⁵, or R⁵ and R¹² together are alkylene or 
alkenylene (either of which may be substituted with 

 
Z¹, Z² and Z³), completing a 4- to 8-membered 

saturated, unsaturated or aromatic ring together 
with the carbon atoms to which they are attached; 
 
   R⁶ is alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, 

cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl, any 
of which may be substituted with Z¹, Z² and Z³; 

   R⁷ is 

(a) hydrogen; 
(b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, 
cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl 

or aralkyl, any of which may be substituted with Z¹, 
Z² and Z³; 
(c) cyano; 
(d) hydroxyl; 
(e) -C(O)H or -C(O)R⁶; 
(f) -CO₂R⁶; or 
(g) -SH, -S(O)nR⁶, -S(O)m-OR⁶, 
-O-S(O)m-R⁶ or -O-S(O)m-OR⁶,
 except when Z⁴ is 
-S(O)n-; 
 
   R⁸ is 


(a) hydrogen; 
(b) -C(O)H or -C(O)R⁶, except when Z⁴ is -C(O)- and 
R⁷ is -C(O)H, -C(O)R⁶ or -CO₂R⁶; or 
(c) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, 
cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl 

or aralkyl, any of which may be substituted with Z¹, 
Z² and Z³; or 
 
   R⁷ and R⁸ together are alkylene or alkenylene (either of 

which may be substituted with Z¹, Z² and Z³), completing a 3- to 8-membered 
saturated, unsaturated or aromatic ring together with 

the nitrogen atom to which they are attached; 
   R⁹ is 


(a) hydrogen; 
(b) hydroxyl; 
(c) -C(O)H or -C(O)R⁶; 
(d) -CO₂R⁶; 
(e) -SH, -S(O)nR⁶, -S(O)m-OR⁶, 
-O-S(O)m-R⁶ or -O-S(O)m-OR⁶; or 
(f) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, 
cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl 

or aralkyl, any of which may be substituted with Z¹, 
Z² and Z³; 
 
   R¹⁰ is 


(a) hydrogen; 
(b) -C(O)H or -C(O)R⁶, except when Z⁵ is -C(O)- and 
R⁹ is -C(O)H, -C(O)R⁶ or -CO₂R⁶; or 
(c) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, 
cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl 

or aralkyl, any of which may be substituted with Z¹, 
Z² and Z³; 
 
   R¹¹ is 


(a) hydrogen; 
(b) hydroxyl or -CO₂R⁶, except when one of R⁹ and 
R¹⁰ is hydroxyl or -CO₂R⁶; 
(c) -C(O)H or -C(O)R⁶; or 
(d) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, 
cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl 

or aralkyl, any of which may be substituted with Z¹, 
Z² and Z³; 
 
or any two of R⁹, R¹⁰ and R¹¹ together are alkylene or alkenylene 

(either of which may be substituted with Z¹, Z² and Z³), completing 
a 3- to 8-membered saturated, unsaturated or aromatic ring 

together with the atoms to which they are attached; 
   Z¹, Z² and Z³ are each independently 


(a) hydrogen; 
(b) halo; 
(c) hydroxy; 
(d) alkyl, alkenyl, aralkyl, alkoxy, aryloxy or aralkoxy; 
(e) -SH, -S(O)nZ⁶, -S(O)m-OH, -S(O)m-OZ⁶, 
-O-S(O)m-Z⁶, -O-S(O)mOH or -O-S(O)m-OZ⁶; 
(f) oxo; 
(g) nitro; 
(h) cyano; 
(i) -C(O)H or -C(O)Z⁶; 
(j) -CO₂H or -CO₂Z⁶; or 
(k) -Z⁴-NZ⁷Z⁸ Z⁴-N(Z¹¹)-Z⁵Z⁶ or 
-Z⁴-N(Z¹¹)-Z⁵-NZ⁷Z⁸; 
 
   Z⁴ and Z⁵ are each independently 


(a) a single bond; 
(b) -Z⁹-S(O)m-Z¹⁰; 
(c) -Z⁹-C(O)-Z¹⁰; 
(d) -Z⁹-C(S)-Z¹⁰; 
(e) -Z⁹-O-Z¹⁰; 
(f) -Z⁹-S-Z¹⁰; 
(g) -Z⁹-O-C(O)-Z¹⁰; or 
(h) alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, 
cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl, any 

of which may be substituted with Z¹, Z² and Z³; 
 
   Z⁶, Z⁷ and Z⁸ are each independently hydrogen, alkyl, 

alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, 
cycloalkenylalkyl, aryl, or aralkyl, or Z⁷ and Z⁸ together are 

alkylene or alkenylene, completing a 3- to 8-membered saturated, 
unsaturated or aromatic ring together with the nitrogen atom to 

which they are attached; 
   Z⁹ and Z¹⁰ are each independently a single bond, 

alkylene, alkenylene or alkynylene, 
   Z¹¹ is 


(a) hydrogen; 
(b) hydroxyl; 
(c) -C(O)H, -C(O)Z⁶ or -CO₂Z⁶, provided that when 
Z¹¹ is -CO₂Z⁶, Z⁶ is other than hydrogen; or 
(d) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, 
cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl 

or aralkyl; 
 
   or any two of Z⁷, Z⁸ and Z¹¹ together are alkylene or 

alkenylene, completing a 3- to 8- membered saturated, 
unsaturated or aromatic ring together with the atoms to which they 

are attached; 
   m is 1 or 2; and 

   n is 0, 1 or 2. 
The compound of Claim 1, wherein R is 
 

with the sulfonamide attached at position 1 or 2 and one of R¹, R² 
and R³ attached at position 5 or 6. 
The compound of Claim 3, wherein one of R¹, R² and 
R³ is -NR⁷R⁸. 
The compound of Claim 4, wherein R⁷ and R⁸ are 
each independently hydrogen, alkyl or C(O)alkyl. 
The compound of Claim 5, wherein R⁷ and R⁸ are 
each independently hydrogen, methyl, methylethyl or acetyl. 
The compound of Claim 3, wherein R⁴, R⁵ and R¹² are 
independently hydrogen, alkyl or halo. 
The compound of Claim 1, having the formula 

The compound of Claim 8, wherein 
R⁷ and R⁸ are each independently hydrogen, alkyl or C(O)alkyl. 
The compound of Claim 9, wherein 
R⁷ and R⁸ are each independently hydrogen, methyl, methylethyl 

or acetyl. 
The compound of Claim 1, wherein R is biphenyl 
which may be substituted with R¹, R² and R³. 
The compound of Claim 11, wherein one of R¹, R² 
and R³ is 4'-alkyl or 4'-branched alkyl. 
The compound of Claim 12, wherein one of R¹, R² 
and R³ is 4'-alkyl. 
The compound of Claim 12, wherein one of R¹, R² 
and R³ is 4'-branched alkyl. 
The compound of Claim 1, which is: 
   N-(6-Chloro-3-pyridazinyl)-5-(dimethylamino)-1-naphthalenesulfonamide;

 
   N-(6-Chloro-5-methyl-3-pyridazinyl)-5-(dimethylamino)-1 

-naphthalenesulfonamide; 
   N-(6-Chloro-4-methyl-3-pyridazinyl)-5-(dimethylamino)-1-naphthalenesulfonamide; 

   N-(6-Chloro-3-pyridazinyl)[1,1'-biphenyl]-2-yl-sulfonamide; 

or 
   N-(6-Chloro-3-pyridazinyl)-4'-(2-methylpropyl)[1,1'-biphenyl]
-2-sulfonamide. 
Use of a compound of any one of Claims 1-15 for 
the manufacture of a medicament for the treatment of endothelin- 

related disorders in a mammal. 
Use of a compound of any one of Claims 1-15 for 
the manufacture of a medicament for the treatment of hyper-tension. 
Use of a compound of any one of Claims 1-15 for 
the manufacture of a medicament for the treatment of renal, 

glomerular or mesangial cell disorders. 
Use of a compound of any one of Claims 1-15 for 
the manufacture of a medicament for the treatment of endotoxemia. 
Use of a compound of any one of Claims 1-15 for 
the manufacture of a medicament for the treatment of ischemia. 
</CLAIMS>
</TEXT>
</DOC>
